Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010

Table 3 clinico-pathological features of the most frequent classes of pancreatic cancer

Classification	Frequency (%)	Author	yr	Survival (5-yr survival after surgical resection)
DIA (incidence per 100 000 patients at risk = 8.37)[69]	85-90[1]	Conlon et al[70]	1996	10%
		Winter et al[71]	2006	18%
		Poultsides et al[72]	2010	19%
SPPN (incidence per 100 000 patients at risk = NA)[69]	0.1-3[73]	Papavramidis et al[74]	2005	95%
IPMN (incidence per 100 000 patients at risk = 0.03)[69]		Shin et al[76]	2010	Benign: 95%
				Malignant: 64%
IPMN with simultaneous DIA: (incidence per 100 000 patients at risk = NA)[69]	5[75]	Poultsides et al[72]	2010	42%
		Fan et al[77]	2010	57%
		Sohn et al[78]	2004	43%
Pancreatoblastoma (incidence per 100 000 patients at risk = NA)[69]	0.50[79]	Dhebri et al[80]	2004	50%
		Saif et al[79]	2007	80%
Undifferentiated (incidence per 100 000 patients at risk = 0.03)[69]	2-7[81]	Paal et al[82]	2001	3% (3-yr survival)
		Connolly et al[83]	1987	5 mo (average survival)
Medullary carcinoma (incidence per 100 000 patients at risk = NA)[69]	NA	Wilentz et al[84]	2000	11%
				14 mo (average survival)
Mucinous cystadenocarcinoma (incidence per 100 000 patients at risk = 0.43)[69]	1	Ridder et al[85]	1996	56%
Adenosquamous carcinoma (incidence per 100 000 patients at risk = 0.05)[69]	4	Madura et al[86]	1999	5-7 mo (median survival)
		Mulkeen et al[87]	2006
Acinar cell carcinoma (incidence per 100 000 patients at risk = 0.02)[69]	2	Holen et al[88]	2002	38 mo after surgical resection (median survival)
				14 mo for unresectable disease (median survival)

DIA: Ductal infiltrating adenocarcinoma; SPPN: Solid pseudo-papillary neoplasm; IPMN: Intraductal papillary nucinous neoplasm; NA: Not applicable.